Ucb S.a Stock Earnings Reports

Key points for investors: UCB delivered a very strong 2025 driven by its five growth drivers, with net sales growth of +35% (constant trend) and total revenues of EUR 7.7bn (up 26%, 29% at CER). BIMZELX (bimekizumab) was the main growth engine, reaching >EUR 2.2bn in 2025 and strong market traction in psoriasis, HS and rheumatology. The company advanced its pipeline: KYGEVVI received U.S. approval and CHMP positive opinion (TK2 deficiency), bepranemab (anti‑tau) received FDA fast‑track designation after positive Phase II signals, and galvokimig was prioritized (continuing development in atopic dermatitis and being advanced into COPD and bronchiectasis). FINTEPLA is being expanded into Rett syndrome and other neurodevelopmental indications. UCB announced a major manufacturing commitment in the U.S. — a planned ~$5bn direct and indirect investment into a mammalian manufacturing site to produce BIMZELX. Financials showed margin expansion (adjusted gross margin ~79.2%), adjusted EBITDA of EUR 2.6bn (up ~79%), improved operating leverage, strong cash generation and full deleveraging of the balance sheet. 2026 guidance: revenues expected to grow high single‑digit to low double‑digit (CER); adjusted EBITDA growth expected high single‑digit to high‑teens (CER) with stronger EBITDA growth versus revenue once adjusted for one‑offs. Key investor considerations/risks: potential gross‑to‑net compression as access expands for BIMZELX (true‑up seen in H2 2025), upcoming loss‑of‑exclusivity impacts (e.g., Briviact), competitive dynamics in immunology (AD/HS/COPD classes), and clinical execution risks inherent to I&I and neurology programs. Management signals disciplined capital allocation: balance sheet flexibility to pursue inorganic opportunities focused on early‑clinical assets that fit UCB capabilities, while avoiding disruption to current launch execution.